Potent Preclinical Antitumor Activity Demonstrated by Janpix’s Selective STAT3 & STAT5 Monovalent Degraders to be presented at the Virtual Annual Meetings of the European Hematology Association and American Association for Cancer Research (Part II)
Retrieved on:
月曜日, 6月 15, 2020
This is the first time that a monovalent small molecule has been shown to degrade both, STAT3 and STAT5.
Key Points:
- This is the first time that a monovalent small molecule has been shown to degrade both, STAT3 and STAT5.
- These compounds show activity across multiple hematologic malignancies including acute myelogenous leukemia (AML) and T-cell prolymphocytic leukemia (T-PLL).
- Data will be shared in poster presentations during the 2020 European Hematology Association Virtual Meeting (Abstract #EP436) starting on Monday, June 15th, and the 2020 American Association for Cancer Research Virtual Annual Meeting II (Abstract #10643) starting on Monday, June 22th.
- Highlights of the presentations include:
Rapid, potent, and highly selective degradation of STAT3 & STAT5 in leukemic cells upon treatment with JPX-1188.